trending Market Intelligence /marketintelligence/en/news-insights/trending/I3ojT2HANnlBWsk30tjWHA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Chi-Med plans US$110M offering of American depositary shares

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Chi-Med plans US$110M offering of American depositary shares

Hutchison China MediTech Ltd. said it is planning to sell US$110 million of its American depositary shares in a public offering.

The Hong Kong-based biopharmaceutical company also plans to grant underwriters a 30-day option to buy up to an additional US$16.5 million of ADSs in total at the same price.

Each ADS represents five ordinary shares of the company.

Chi-Med plans to use net proceeds for research and development and to expand its commercialization capabilities.

BofA Securities Inc., Goldman Sachs (Asia) LLC and Morgan Stanley & Co. LLC are acting as joint global coordinators and joint book runners for the offer.

Chi-Med develops therapies for cancer and autoimmune diseases.